Periodic Reporting for period 1 - IT4-TALL (Clinical translation of a novel CD1a-directed CAR for relapse/refractory cortical T-cell Acute Lymphoblastic Leukemia: feasibility, efficacy and safety)

Immunotherapy has revolutionized cancer treatment over the last decade. Adoptive cell immunotherapy with T-cells genetically redirected to a tumor-specific antigen using CARs has achieved impressive complete response rates in (R/R) “advanced” B-cell malignancies. However...